242 related articles for article (PubMed ID: 19016150)
1. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
[TBL] [Abstract][Full Text] [Related]
2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
9. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
10. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
[TBL] [Abstract][Full Text] [Related]
11. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
Heerspink HL; Greene T; Lewis JB; Raz I; Rohde RD; Hunsicker LG; Schwartz SL; Aronoff S; Katz MA; Eisner GM; Mersey JH; Wiegmann TB;
Nephrol Dial Transplant; 2008 Jun; 23(6):1946-54. PubMed ID: 18089623
[TBL] [Abstract][Full Text] [Related]
12. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria.
Deerochanawong C; Kornthong P; Phongwiratchai S; Serirat S
J Med Assoc Thai; 2001 Feb; 84(2):234-41. PubMed ID: 11336083
[TBL] [Abstract][Full Text] [Related]
13. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
[TBL] [Abstract][Full Text] [Related]
14. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
15. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; García J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
16. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
Schjoedt KJ
Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
[TBL] [Abstract][Full Text] [Related]
17. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
Guney I; Selcuk NY; Altintepe L; Atalay H; Başarali MK; Büyükbaş S
Ren Fail; 2009; 31(9):779-84. PubMed ID: 19925284
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
20. Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
Campese VM; Park J
J Hypertens; 2006 Nov; 24(11):2157-9. PubMed ID: 17053534
[No Abstract] [Full Text] [Related]
[Next] [New Search]